Compare Petróleo Brasileiro SA (PBR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Petróleo Brasileiro SA vs Tango Therapeutics Inc. — how do they compare? Petróleo Brasileiro SA trades at $25.79 (market cap $159.16B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Petróleo Brasileiro SA is far larger — about 42.6× Tango Therapeutics Inc.'s market cap, and Petróleo Brasileiro SA pays a 6.46% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Petróleo Brasileiro SA for 26 Days and Tango Therapeutics Inc. for 0 Days on average.
| PBR | TNGX | |
|---|---|---|
Market Cap | $159.16B | $3.74B |
Volume | 19,717,211 | 3,438,781 |
Sector | Energy | Health |
52-Week High | $25.94 | $32.90 |
52-Week Low | $11.54 | $7.50 |
Typical Hold Time | 26 Days | 0 Days |
Enterprise Value | $219.58B | $2.76B |
Dividend Yield | 6.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Petrobras (PBR) trades at $25.50, up 0.31% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with a P/E of 6.55, net income margin of 24.52%, and Q2 2026 earnings beat. Recent developments include new oil discoveries and LNG supply agreements, supporting growth prospects. Analyst consensus is bullish with 50% buy ratings, though the current price exceeds the $22.33 consensus target.
PBR offers attractive valuation metrics and strong profitability, but faces execution risks from capital-intensive projects and political exposure. The stock's technical overbought condition near resistance levels suggests potential near-term consolidation. Long-term growth drivers include production expansion and strategic partnerships, though investors should monitor debt levels and Brazilian regulatory environment.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
